Published in Drugs on January 01, 1987
Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers. Antimicrob Agents Chemother (1991) 1.33
Microbiological transformation of enrofloxacin by the fungus Mucor ramannianus. Appl Environ Microbiol (2000) 1.02
Milk and yoghurt do not impair the absorption of ofloxacin. Br J Clin Pharmacol (1992) 1.00
Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process. Antimicrob Agents Chemother (1996) 0.84
Scaling basic toxicokinetic parameters from rat to man. Environ Health Perspect (1996) 0.83
Penetration of ofloxacin into human lung tissue following a single oral dose of 200 milligrams. Antimicrob Agents Chemother (1991) 0.81
Unique aspects of quinolone pharmacokinetics. Clin Pharmacokinet (1989) 0.78
Pharmacokinetic studies of CP-74,667, a new quinolone, in laboratory animals. Antimicrob Agents Chemother (1992) 0.75
The pharmacokinetics and tissue penetration of ofloxacin. J Antimicrob Chemother (1984) 4.15
Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother (1985) 4.07
Norfloxacin disposition after sequentially increasing oral doses. Antimicrob Agents Chemother (1983) 3.53
Pharmacokinetics and tissue penetration of enoxacin. Antimicrob Agents Chemother (1984) 2.79
Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. Eur J Clin Microbiol (1986) 2.00
Absolute oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother (1986) 1.97
[Clinical pharmacology of ofloxacin: a new chemotherapeutic agent belonging to the gyrase inhibitor group]. Infection (1986) 1.85
Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers. Antimicrob Agents Chemother (1984) 1.63
Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. J Antimicrob Chemother (1986) 1.29
Dose ranging study and constant infusion evaluation of ciprofloxacin. Antimicrob Agents Chemother (1986) 1.23
Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses. Eur J Clin Microbiol (1986) 1.16
The pharmacokinetics and tissue penetration of enoxacin and norfloxacin. J Antimicrob Chemother (1984) 0.99
Single and multiple dose pharmacokinetics of ciprofloxacin. Eur J Clin Microbiol (1986) 0.79
[Biotransformation of selected gyrase inhibitors]. Infection (1986) 0.78
The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. Infection (1986) 0.75
Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother (1985) 4.07
The structure of the first coordination shell in liquid water. Science (2004) 3.31
Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother (1987) 3.09
[Azlocillin and mezlocillin: two new semisynthetic acylureido-penicillins (author's transl)]. Infection (1977) 2.54
Absence of Mn-centered oxidation in the S(2) --> S(3) transition: implications for the mechanism of photosynthetic water oxidation. J Am Chem Soc (2001) 2.51
Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000. Antimicrob Agents Chemother (1979) 2.23
A program for non-linear regression analysis to be used on desk-top computers. Comput Programs Biomed (1980) 2.03
Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. Eur J Clin Microbiol (1986) 2.00
Small intestinal structure and function in patients infected with human immunodeficiency virus (HIV): evidence for HIV-induced enteropathy. Ann Intern Med (1989) 1.99
67 Ga for tumor scanning. J Nucl Med (1972) 1.97
Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol (1985) 1.86
High-level sensitivity of quantitative pp65 cytomegalovirus (CMV) antigenemia assay for diagnosis of CMV disease in AIDS patients and follow-up. J Clin Microbiol (1996) 1.81
Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother (2000) 1.80
Multicentre study of a new enzymatic method of cholesterol determination. J Clin Chem Clin Biochem (1984) 1.77
Application of the polymerase chain reaction in the diagnosis of pulmonary toxoplasmosis in immunocompromised patients. Eur J Clin Microbiol Infect Dis (1992) 1.71
High diagnostic accuracy of NT-proBNP for cardiac origin of pleural effusions. Eur Respir J (2006) 1.64
Respiratory failure in patients undergoing allogeneic hematopoietic SCT--a randomized trial on early non-invasive ventilation based on standard care hematology wards. Bone Marrow Transplant (2011) 1.63
Isolated failure of autonomic noradrenergic neurotransmission. Evidence for impaired beta-hydroxylation of dopamine. N Engl J Med (1986) 1.55
[Correlation of thromboplastin times in dicumarol treated patients using various preparations of thrombokinase]. Z Klin Chem Klin Biochem (1970) 1.53
Hypersensitivity pneumonitis associated with the use of temozolomide. Eur Respir J (2009) 1.47
Comparative pharmacokinetics of cefoperazone and cefotaxime. Clin Ther (1980) 1.46
Pharmacodynamics of fluoroquinolones. Clin Infect Dis (1998) 1.42
The anaerobic threshold in cystic fibrosis: comparison of V-slope method, lactate turn points, and Conconi test. Pediatr Pulmonol (1998) 1.42
Pharmacokinetics of amoxicillin and clavulanic acid administered alone and in combination. Antimicrob Agents Chemother (1982) 1.42
Mn K-edge XANES and Kbeta XES studies of two Mn-oxo binuclear complexes: investigation of three different oxidation states relevant to the oxygen-evolving complex of photosystem II. J Am Chem Soc (2001) 1.40
Azithromycin--review of key chemical, pharmacokinetic and microbiological features. J Antimicrob Chemother (1996) 1.40
Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. Antimicrob Agents Chemother (1983) 1.39
Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora. Scand J Infect Dis (2001) 1.37
Comparative pharmacokinetics of apalcillin and piperacillin. Antimicrob Agents Chemother (1984) 1.28
[Comparative clinical pharmacology of gentamicin, sisomicin, and tobramycin]. Antimicrob Agents Chemother (1975) 1.26
Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. Antimicrob Agents Chemother (1999) 1.24
Reliability of drug history in analgesic users. Lancet (1984) 1.21
Determination of apalcillin and its metabolites in human body fluids by high-pressure liquid chromatography. Antimicrob Agents Chemother (1982) 1.19
Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Antimicrob Agents Chemother (1996) 1.19
Tricuspid annular plane systolic excursion assessed using MRI for semi-quantification of right ventricular ejection fraction. Br J Radiol (2012) 1.14
Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol (1989) 1.12
Localized pulmonary infection associated with Mycobacterium tilburgii in an HIV-infected patient. Infection (2005) 1.12
[Congenital nonspherocytic hemolytic anemia, cataract and glucose-6-phosphate dehydrogenase deficiency]. Dtsch Med Wochenschr (1966) 1.11
Determination of cefmenoxime in human body fluids by high-performance liquid chromatography. Eur J Clin Microbiol (1983) 1.08
Multiple dose pharmacokinetics and therapeutic results with ceftazidime. J Antimicrob Chemother (1983) 1.07
Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam. Antimicrob Agents Chemother (1983) 1.03
Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers. J Antimicrob Chemother (1992) 1.02
Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother (2000) 1.01
Chlamydia pneumoniae as a cause of community-acquired pneumonia in hospitalized patients in Berlin. Clin Infect Dis (1996) 1.01
Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother (1992) 1.00
Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother (1989) 1.00
Biliary excretion and pharmacokinetics of cefoperazone in humans. J Antimicrob Chemother (1983) 0.99
Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother (2001) 0.99
Measurement of lung density by computed tomography. J Comput Assist Tomogr (1978) 0.99
Chondrotoxicity and toxicokinetics of sparfloxacin in juvenile rats. Antimicrob Agents Chemother (1998) 0.99
Cefotaxime in bronchopulmonary infections--a clinical and pharmacological study. J Antimicrob Chemother (1980) 0.98
Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers. Antimicrob Agents Chemother (1988) 0.97
Liquid chromatographic determination of ciprofloxacin and some metabolites in human body fluids. J Clin Chem Clin Biochem (1986) 0.97
High-resolution X-ray spectroscopy of rare events: a different look at local structure and chemistry. J Synchrotron Radiat (2001) 0.96
[Clinical aspects of endocarditis]. Immun Infekt (1991) 0.96
[Blood levels of cephalothin in normal and impaired renal function]. Int Z Klin Pharmakol Ther Toxikol (1972) 0.96
Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibiotic. J Infect Dis (1976) 0.94
Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J (2003) 0.92
Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. Antimicrob Agents Chemother (1994) 0.92
Concentrations of ofloxacin in human bone and in cartilage. J Antimicrob Chemother (1990) 0.92
Influence of design and bearing material on polyethylene wear particle generation in total knee replacement. Acta Biomater (2009) 0.91
Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection. Antimicrob Agents Chemother (1998) 0.91
Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections. Antimicrob Agents Chemother (1987) 0.90